SAB Biotherapeutics falls after launching stock offering

Jefferies Financial

17/03/2026 21:17

** Shares of SAB Biotherapeutics SABS.O down 4.2% to $3.90 after hours following planned equity raise news

** Miami Beach, Florida-based biopharma firm commences offering of stock and pre-funded warrants without disclosing deal size

** Co intends to use net offering proceeds primarily to fund development of lead product candidate, SAB-142, its immunotherapy designed to delay the onset or progression of Type 1 Diabetes (T1D)

** Jefferies, UBS, Citigroup and Barclays joint bookrunners

** Co has ~$207 mln market cap, based on ~50.95 mln shares outstanding

** Stock closed up 3.3% at $4.07 on Tues, up ~9% YTD and ~150% over the past 12 months

** All 8 analysts covering the stock are bullish including 3 "strong buy" ratings; median PT $7, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))